GO:0097194 execution phase of apoptosis: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097194 (execution phase of apoptosis) is the terminal stage of apoptosis, beginning with controlled cellular breakdown by effector caspases and other effector molecules such as cathepsins and calpains.
• Hallmark morphological events include cell rounding, pseudopod retraction, pyknosis, chromatin condensation, karyorrhexis, plasma membrane blebbing, and fragmentation into apoptotic bodies.
• The execution phase is driven by effector caspases (e.g., CASP3, CASP6, CASP7) that cleave hundreds of substrates, but caspase-independent effectors also contribute.
• Both nuclear and extranuclear (cytoplasmic) events are integral to the execution phase, including cytoskeletal and organelle dismantling.
• Dysregulation of the execution phase is implicated in cancer, neurodegeneration, and autoimmune disease, making it a key therapeutic target.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of execution-phase genes in disease and drug response.
Description
The execution phase of apoptosis (GO:0097194) is the final, irreversible stage of programmed cell death in which the cell is systematically dismantled through the action of effector caspases and other effector molecules such as cathepsins and calpains. This phase is defined by a stereotyped sequence of morphological changes: cell rounding, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing, and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. Understanding this process is fundamental to cell biology because it determines the outcome of apoptotic signaling and shapes tissue homeostasis, development, and disease. Researchers study the execution phase to identify therapeutic targets in cancer, neurodegeneration, and autoimmune disorders, and to interpret how cells respond to chemotherapy, radiation, and targeted agents. The execution phase is not a passive consequence of upstream signaling; it is an actively regulated process involving proteolysis, cytoskeletal reorganization, and organelle disassembly. This article provides a research-grade overview of GO:0097194, its molecular players, disease relevance, and the CRISPR-based methods used to interrogate it.
execution phase of apoptosis At A Glance
| GO ID | GO:0097194 |
|---|---|
| GO term | execution phase of apoptosis |
| Ontology | biological_process |
| Synonym | apoptosis, execution phase of apoptotic process |
| Major function | Controlled dismantling of the cell by effector caspases and other effector molecules, leading to cell death |
| Key morphological features | Cell rounding, pseudopod retraction, pyknosis, chromatin condensation, karyorrhexis, membrane blebbing, apoptotic body formation |
| Key molecular effectors | Effector caspases (CASP3, CASP6, CASP7), cathepsins, calpains |
| Subcellular compartments | Cytoplasm, nucleus, cytoskeleton, mitochondria, plasma membrane |
| Related processes | Intrinsic and extrinsic apoptosis, caspase activation, cytoskeletal reorganization |
What Is GO:0097194?
GO:0097194 (execution phase of apoptosis) is a biological process stage that starts with the controlled breakdown of the cell through the action of effector caspases or other effector molecules (e.g., cathepsins, calpains). Key steps include rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing, and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
Why Is execution phase of apoptosis Important in Cell Biology?
The execution phase of apoptosis is the point of no return in programmed cell death, and its proper regulation is essential for development, tissue homeostasis, and immune surveillance. Defects in execution-phase components can lead to failed apoptosis, contributing to cancer and autoimmunity, while excessive execution-phase activity contributes to neurodegeneration and ischemic injury. Because the execution phase is the terminal common pathway of both intrinsic and extrinsic apoptosis, it represents a convergence point for therapeutic intervention. Understanding its molecular mechanisms is therefore critical for designing drugs that selectively kill cancer cells or protect neurons.
• The execution phase is the terminal common pathway of intrinsic and extrinsic apoptosis, integrating diverse death signals.
• Effector caspases such as CASP3, CASP6, and CASP7 cleave hundreds of substrates to dismantle the cell.
• Caspase-independent effectors (cathepsins, calpains) can also drive execution-phase morphology.
• Cytoskeletal and nuclear events are coordinated during execution, including microtubule remodeling and chromatin condensation.
• Failed execution-phase apoptosis is a hallmark of cancer and autoimmune disease.
• Excessive execution-phase activity contributes to neurodegeneration and ischemia-reperfusion injury.
• Execution-phase morphology is used as a diagnostic and research readout of apoptosis.
• The execution phase is a target for chemotherapy, radiation, and targeted anticancer agents.
• CRISPR models of execution-phase genes enable causal studies of drug resistance and disease.
• Understanding execution-phase mechanisms informs development of apoptosis-modulating therapeutics.
What Happens During execution phase of apoptosis?
Initiation by effector caspases
In simple terms: The execution phase begins when effector caspases are activated and start cutting key cellular proteins.
The execution phase starts with the controlled breakdown of the cell through the action of effector caspases or other effector molecules such as cathepsins and calpains. Effector caspases, including CASP3, CASP6, and CASP7, are activated downstream of initiator caspases and cleave a broad spectrum of substrates, leading to the morphological and biochemical changes characteristic of apoptosis. This proteolytic cascade is a defining feature of the execution phase and is required for most of the classical apoptotic hallmarks.
Cell rounding and pseudopod retraction
In simple terms: The cell pulls in its extensions and becomes round as the cytoskeleton is reorganized.
Key steps of the execution phase include rounding-up of the cell and retraction of pseudopodes. These changes are driven by reorganization of the actin and microtubule cytoskeleton, and apoptotic microtubules play emerging roles during the execution phase. Cytoskeletal dismantling contributes to the loss of cell shape and adhesion that precedes membrane blebbing and fragmentation.
Pyknosis and chromatin condensation
In simple terms: The cell and its nucleus shrink, and the DNA becomes tightly packed.
Reduction of cellular volume (pyknosis) and chromatin condensation are hallmark execution-phase events. Nuclear events, including chromatin condensation and nuclear fragmentation (karyorrhexis), are coordinated with cytoplasmic dismantling. The nucleus plays both signaling and execution roles in apoptosis, and its dismantling is a key step in the execution phase.
Membrane blebbing and apoptotic body formation
In simple terms: The cell membrane forms bubbles and then breaks into small packages called apoptotic bodies.
Plasma membrane blebbing and fragmentation of the cell into apoptotic bodies are late execution-phase steps. These morphological changes are driven by actomyosin contraction and are used as diagnostic features of apoptosis. When the execution phase is completed, the cell has died, and apoptotic bodies are typically cleared by phagocytes.
Extranuclear and caspase-independent execution
In simple terms: Parts of the cell outside the nucleus, and even some non-caspase enzymes, help finish the job.
Extranuclear apoptosis highlights the role of the cytoplasm in the execution phase, including organelle dismantling and cytoskeletal changes. In addition to caspases, other effector molecules such as cathepsins and calpains can contribute to execution-phase morphology. This redundancy ensures that the cell is dismantled even when canonical caspase pathways are compromised.
Key Genes Involved in GO:0097194 execution phase of apoptosis
The following genes and proteins are central to the execution phase of apoptosis, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CASP3 | Effector caspase that cleaves key substrates during execution | Knockout and point-mutation models to study apoptosis resistance |
| CASP6 | Effector caspase involved in nuclear and cytoskeletal dismantling | Target for neurodegenerative and cancer studies |
| CASP7 | Effector caspase that amplifies caspase cascade | Knockout models to assess redundancy with CASP3 |
| CASP8 | Initiator caspase linking extrinsic signals to execution | Knockout models for death receptor signaling |
| CASP9 | Initiator caspase in intrinsic apoptosis | Knockout models for mitochondrial apoptosis |
| BAX | Pro-apoptotic BCL-2 family member promoting mitochondrial permeabilization | Knockout and knock-in models for apoptosis initiation |
| BAK1 | Pro-apoptotic BCL-2 family member redundant with BAX | Double knockout models for apoptosis blockade |
| BCL2 | Anti-apoptotic protein inhibiting execution | Overexpression models for apoptosis resistance |
| APAF1 | Apoptosome component activating CASP9 | Knockout models for intrinsic apoptosis |
| CYCS | Cytochrome c released from mitochondria to activate apoptosome | Knock-in tagging for release dynamics |
| DFFA | DNA fragmentation factor subunit involved in chromatin condensation | Knockout models for nuclear execution |
| DFFB | Caspase-activated DNase for DNA fragmentation | Knockout models for karyorrhexis |
| GSDME | Gasdermin E cleaved by CASP3 to cause membrane permeabilization | Knockout models for secondary necrosis |
| ROCK1 | Rho kinase driving membrane blebbing | Knockout and inhibitor studies for blebbing |
| ACTB | Actin cytoskeleton component reorganized during execution | Tagged knock-in for live imaging |
| TUBA1A | Microtubule component with roles in apoptotic microtubules | Knockout models for cytoskeletal execution |
| CTSB | Cathepsin B, a caspase-independent effector | Knockout models for lysosomal apoptosis |
| CAPN1 | Calpain 1, a calcium-dependent effector | Knockout models for caspase-independent death |
How Is execution phase of apoptosis Regulated?
The execution phase of apoptosis is regulated at multiple levels. Effector caspases are controlled by inhibitor of apoptosis proteins (IAPs) and by upstream initiator caspases that respond to intrinsic and extrinsic signals. The intrinsic pathway is regulated by BCL-2 family proteins, which determine mitochondrial outer membrane permeabilization and cytochrome c release. The extrinsic pathway is regulated by death receptor signaling and caspase-8 activation. Cytoskeletal dynamics, including apoptotic microtubules, also modulate execution-phase progression. Additionally, caspase-independent effectors such as cathepsins and calpains are regulated by lysosomal integrity and calcium signaling. These layers of regulation ensure that execution proceeds only when appropriate and can be modulated by therapeutic agents.
execution phase of apoptosis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CASP3 | Cancer drug resistance, neurodegeneration | Knockout and point-mutation cell lines |
| BCL2 | Lymphoma, apoptosis evasion | Overexpression and knock-in models |
| BAX | Cancer, neurodegeneration | Knockout and knock-in models |
| DFFB | Nuclear execution defects, cancer | Knockout models for DNA fragmentation |
| GSDME | Inflammation, secondary necrosis | Knockout and overexpression models |
Cancer
Evasion of apoptosis is a hallmark of cancer, and defects in the execution phase contribute to tumor survival and drug resistance. Loss of effector caspases or overexpression of anti-apoptotic proteins such as BCL2 can block execution-phase dismantling, allowing cancer cells to survive chemotherapy. Conversely, agents that activate execution-phase caspases are used in cancer therapy.
Neurodegeneration
Excessive or inappropriate execution-phase apoptosis contributes to neuronal loss in neurodegenerative diseases. Caspase activation and execution-phase morphology have been observed in models of Alzheimer's disease, Parkinson's disease, and stroke. Targeting execution-phase components is a potential neuroprotective strategy.
Autoimmune and inflammatory disease
Impaired clearance of apoptotic cells or defective execution-phase apoptosis can lead to autoimmunity and chronic inflammation. When execution-phase cells are not properly dismantled, they may release immunogenic contents, contributing to disease.
From execution phase of apoptosis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is CASP3 required for execution-phase morphology? | CASP3 knockout cell line |
| Does a point mutation in CASP3 affect substrate cleavage? | CASP3 point-mutation knock-in |
| How does BCL2 overexpression block execution? | BCL2 overexpression cell line |
| Where is cytochrome c released during execution? | CYCS tagged knock-in |
| What is the role of GSDME in membrane permeabilization? | GSDME knockout and overexpression |
| Can caspase-independent effectors compensate? | CTSB/CAPN1 double knockout |
How to Study the execution phase of apoptosis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Live-cell imaging | Morphological changes (blebbing, rounding) | Tracking execution-phase dynamics |
| Caspase activity assay | Effector caspase activity | Confirming execution-phase entry |
| Proteomics | Caspase substrate cleavage | Mapping execution-phase proteolysis |
| CRISPR knockout | Gene requirement for execution | Functional validation of candidate genes |
| CRISPR library screening | Genome-wide modifiers of execution | Identifying resistance/sensitivity genes |
| Flow cytometry | Apoptotic body formation, DNA content | Quantifying execution-phase cells |
| Electron microscopy | Ultrastructural traits of apoptosis | Detailed morphological analysis |
| Western blot | Caspase cleavage and substrate processing | Biochemical confirmation of execution |
Morphological imaging
Live-cell and fixed-cell imaging are used to visualize execution-phase hallmarks such as cell rounding, membrane blebbing, chromatin condensation, and apoptotic body formation. Time-lapse microscopy with fluorescent reporters allows tracking of these events in real time.
Caspase activity assays
Caspase activity is measured using fluorogenic or luminescent substrates, and effector caspase activation is a key readout of the execution phase. These assays are used to confirm that cells have entered the execution phase.
Proteomics and substrate identification
Proteomic approaches identify caspase substrates cleaved during the execution phase, providing a molecular map of dismantling events. These studies reveal the breadth of execution-phase proteolysis.
CRISPR-based functional genomics
CRISPR knockout and library screening are used to identify genes required for execution-phase apoptosis and to dissect resistance mechanisms. These methods enable causal testing of candidate execution-phase genes.
How CRISPR Can Be Used to Study GO:0097194 execution phase of apoptosis
Knockout
CRISPR knockout of execution-phase genes such as CASP3, CASP6, CASP7, BAX, and BAK1 is used to test their requirement for apoptosis and to model drug resistance. Knockout cell lines provide clean genetic backgrounds for studying redundancy and compensation.
Point Mutation
Point mutations in effector caspases or their substrates can be introduced to dissect catalytic activity, substrate specificity, and phosphorylation sites. These models help distinguish catalytic from non-catalytic functions.
Knock-in
Knock-in of tagged versions of execution-phase proteins (e.g., fluorescent tags on CYCS or ACTB) enables live imaging of their localization and dynamics during apoptosis. Knock-in of disease-associated variants can model human mutations.
Overexpression
Overexpression of anti-apoptotic proteins such as BCL2 or of execution-phase effectors is used to study apoptosis resistance or sensitization. Overexpression models are valuable for drug screening and mechanism studies.
How EDITGENE Supports execution phase of apoptosis Research
Researchers studying execution phase of apoptosis-related genes often need to determine whether a candidate gene is causally involved in the dismantling process, whether a specific mutation alters its function, or whether its expression level modulates drug sensitivity. CRISPR-based models provide the precision required to answer these questions in relevant cell backgrounds.
Contact EDITGENE today to design your custom CRISPR model for execution phase of apoptosis research.
Frequently Asked Questions About execution phase of apoptosis
What is the execution phase of apoptosis?
The execution phase of apoptosis (GO:0097194) is the terminal stage of programmed cell death in which the cell is dismantled by effector caspases and other effector molecules, leading to cell rounding, pyknosis, chromatin condensation, membrane blebbing, and apoptotic body formation.
What genes are involved in the execution phase of apoptosis?
Key genes include effector caspases (CASP3, CASP6, CASP7), BCL-2 family members (BAX, BAK1, BCL2), APAF1, CYCS, DFFA, DFFB, GSDME, ROCK1, and caspase-independent effectors such as CTSB and CAPN1.
What are the morphological hallmarks of the execution phase?
Hallmarks include cell rounding, pseudopod retraction, pyknosis, chromatin condensation, karyorrhexis, plasma membrane blebbing, and fragmentation into apoptotic bodies.
How is the execution phase different from the initiation phase?
The initiation phase involves upstream signaling and caspase activation, while the execution phase is the terminal dismantling stage driven by effector caspases and other effector molecules.
Can apoptosis occur without caspases?
Yes, caspase-independent effectors such as cathepsins and calpains can contribute to execution-phase morphology.
What is the role of the nucleus in the execution phase?
The nucleus participates in both signaling and execution, including chromatin condensation and nuclear fragmentation (karyorrhexis).
How do researchers study the execution phase?
Common methods include live-cell imaging, caspase activity assays, proteomics, flow cytometry, electron microscopy, and CRISPR-based functional genomics.
What diseases are linked to defects in the execution phase?
Defects are linked to cancer, neurodegeneration, autoimmune disease, and inflammatory conditions.
What is the role of GSDME in the execution phase?
GSDME is cleaved by CASP3 and causes membrane permeabilization, linking execution-phase apoptosis to secondary necrosis and inflammation.
How can CRISPR help study the execution phase?
CRISPR knockout, point mutation, knock-in, overexpression, and library screening enable causal dissection of execution-phase genes and their roles in disease and drug response.
Conclusion
The execution phase of apoptosis (GO:0097194) is the terminal, actively regulated dismantling stage of programmed cell death, driven by effector caspases and other effector molecules. Its morphological and molecular hallmarks are well defined, and its dysregulation contributes to cancer, neurodegeneration, and autoimmune disease. CRISPR-based models provide powerful tools to dissect the causal roles of execution-phase genes, and continued research will inform therapeutic strategies targeting this process.
References
- 1. Mustafa M et al.. 2024. Apoptosis: A Comprehensive Overview of Signaling Pathways, Morphological Changes, and Physiological Significance and Therapeutic Implications.. Cells 13(22) PMID: 39594587
- 2. Lossi L. 2022. The concept of intrinsic versus extrinsic apoptosis.. Biochem J 479(3):357-384 PMID: 35147165
- 3. Oropesa Ávila M et al.. 2015. Emerging roles of apoptotic microtubules during the execution phase of apoptosis.. Cytoskeleton (Hoboken) 72(9):435-46 PMID: 26382917
- 4. Snigirevskaya ES et al.. 2019. Ultrastructural traits of apoptosis.. Cell Biol Int 43(7):728-738 PMID: 30969020
- 5. Mills JC et al.. 1999. Extranuclear apoptosis. The role of the cytoplasm in the execution phase.. J Cell Biol 146(4):703-8 PMID: 10459006
- 6. Prokhorova EA et al.. 2015. Role of the nucleus in apoptosis: signaling and execution.. Cell Mol Life Sci 72(23):4593-612 PMID: 26346492
- 8. Moffitt KL et al.. 2010. From sentencing to execution--the processes of apoptosis.. J Pharm Pharmacol 62(5):547-62 PMID: 20609056
